Search Results

You are looking at 71 - 80 of 2,573 items for :

  • Refine by Access: Content accessible to Me x
Clear All
Full access

CLO22-045: Gastrointestinal Safety Profile of Sonic Hedgehog Inhibitors in Basal Cell Carcinoma (BCC): A Systematic Review and Meta-analysis

Muhammad Zain Farooq, Mishal Shan Siddiqui, Syed Ali Farhan, Mahima Khatri, Syed Hamza Bin Waqar, Saad Khalid, and Ankit Mangla

reporting adverse events (AE) were excluded. All AEs were reported for phase II trials, while toxicities occurring up to the maximally tolerated dose (MTD) were noted for patients in phase I dose-escalation trials. Results were pooled via Review Manager v5

Full access

EPR21-037: Prevalence of Low HER2 Expression Among HER2 Negative Metastatic Breast Cancer Patients in U.S: Multi-Site, Retrospective Chart Review Study

Sandhya Mehta, Winghan Kwong, Angelica Falkenstein, Melissa Pavilack, and Jonathan Kish

Provider Extended Network (OPEN) who had treated ≥1 BC patient in the past 12 months (n=504) were invited to participate in a retrospective chart review study. Participating physicians submitted data for up to 5 HER2-ve mBC patients who had received any

Full access

Survivorship Care Planning: Why Is It Taking So Long?

Sarah A. Birken and Deborah K. Mayer

clearly and effectively explained.” The objective of the IOM's recommendation was to promote care coordination, communication, and record-keeping efficiency. Although there are other survivors with active disease, this review focuses on patients ending

Full access

Carcinoma in situ of the Urinary Bladder: Review of Clinicopathologic Characteristics with an Emphasis on Aspects Related to Molecular Diagnostic Techniques and Prognosis

Nalan Nese, Ruta Gupta, Matthew H. T. Bui, and Mahul B. Amin

Edited by Kerrin G. Robinson

JI . Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases . Am J Surg Pathol 2006 ; 30 : 883 – 891 . 33 Zincke H Utz DC Farrow GM . Review of Mayo Clinic experience with carcinoma in situ

Full access

Long-Term Outcomes of Myeloid Growth Factor Treatment

Gary H. Lyman and David C. Dale

Controlled Trials of Long-Term Outcomes A systematic review recently reported on randomized controlled trials in adult patients with solid tumors or lymphoma undergoing systemic chemotherapy with or without primary G-CSF support with a follow-up of at least

Full access

HSR20-098: A Systematic Literature Review of First-Line (1L) Treatments for Patients With MGMT (O-6-Methylguanine-DNA Methyl Transferase) Methylated and Unmethylated Glioblastoma Multiforme (GBM)

Gautamjeet Singh Mangat, Roelien Postema, Shweta Takyar, Anagha Gogate, and Alex Z. Fu

need. We reviewed published literature to assess the clinical performance of various interventions in newly diagnosed GBM by MGMT methylation status. Methods: An SLR was conducted from database inception through October 29, 2018, in accordance with

Full access

BPI20-013: A Systematic Review and Meta-Analysis on Mucocutaneous Toxicities Associated With Upfront Use of Immune Checkpoint Inhibitor and Anti-Angiogenic Tyrosine Kinase Inhibitor Combinations for Advanced Renal Cell Carcinoma

Nusrat Jahan, Francis Mogollon-Duffo, Miguel Quirch, Lukman Tijani, and Shabnam Rehman

for advanced renal cell carcinoma (aRCC). When used individually, both ICIs and VEGFis have significant mucocutaneous toxicities. We performed a systematic review and meta-analysis of phase 3 randomized controlled trials (RCTs) to determine the

Full access

Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma

Ritesh R. Kotecha, Ronan Flippot, Taylor Nortman, Annalisa Guida, Sujata Patil, Bernard Escudier, Robert J. Motzer, Laurence Albiges, and Martin H. Voss

in mRCC and characterize outcomes in this specific patient population. Patients and Methods After obtaining Institutional Review Board approval at Gustave Roussy and Memorial Sloan Kettering Cancer Center, a retrospective multicenter chart

Full access

The Role of Maintenance Therapy in the Treatment of Multiple Myeloma

Ashraf Z. Badros

survival with maintenance thalidomide. (A) All trials. (B) Excluding Barlogie 2006. Abbreviations: HR, hazard ratio; OS, overall survival; SE, standard error. Adapted from Hicks LK, Haynes AE, Reece DE, et al. A meta-analysis and systematic review of

Full access

Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer?

Yifan Wang, Adeline Cuggia, Yen-I Chen, Josée Parent, Agatha Stanek, Robert E. Denroche, Amy Zhang, Robert C. Grant, Céline Domecq, Bryn Golesworthy, Chaya Shwaartz, Ayelet Borgida, Spring Holter, Julie M. Wilson, George Chong, Grainne M. O’Kane, Jennifer J. Knox, Sandra E. Fischer, Steven Gallinger, Zu-Hua Gao, William D. Foulkes, Kevin A. Waschke, and George Zogopoulos

compared with the general population. To ascertain study eligibility, a genetic counselor (A. Cuggia) obtained a personal and, at minimum, a 3-generation family history and verified clinical diagnoses through review of medical records. Participants were